Humacyte (HUMA) Non-Current Debt (2020 - 2026)

Humacyte (HUMA) has reported Non-Current Debt for 7 consecutive years, with $36.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Debt fell 45.32% year-over-year to $36.3 million in Q2 2026; TTM through Jun 2026 was $36.3 million, a 45.32% decrease from a year earlier, with the FY2025 full-year figure at $35.4 million, changed N/A from the prior year.
• Non-Current Debt was $36.3 million for Q2 2026 at Humacyte, up from $35.9 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $66.4 million in Q2 2025 and troughed at $16.4 million in Q1 2023.
• A 5-year average of $39.4 million and a median of $36.2 million in 2023 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 253.19% in 2024 and slumped 71.55% in 2025, its largest moves.
• Over 5 years, Non-Current Debt stood at $20.3 million in 2022, then jumped by 89.81% to $38.6 million in 2023, then surged by 60.92% to $62.1 million in 2024, then tumbled by 42.94% to $35.4 million in 2025, then rose by 2.48% to $36.3 million in 2026.
• The last three Non-Current Debt figures came in at $36.3 million (Q2 2026), $35.9 million (Q1 2026), and $35.4 million (Q4 2025), per Business Quant data.